Chris Mason, PhD, Co-founder and Chief Science Officer at AvroBio, a publicly held clinical-stage, gene therapy company based in Cambridge, Massachusetts. He also is a professor of cell and gene therapy in the Advanced Centre for Biochemical Engineering, University College London, working on the clinical translation and commercialization of cell and gene therapies. He has a multidisciplinary track record, spanning R&D, clinical practice, bioprocessing, regulation, healthcare economics, reimbursement and business.
Chris Mason, PhD, Co-founder and Chief Science Officer at AvroBio, a publicly held clinical-stage, gene therapy company based in Cambridge, Massachusetts. He also is a professor of cell and gene therapy in the Advanced Centre for Biochemical Engineering, University College London, working on the clinical translation and commercialization of cell and gene therapies. He has a multidisciplinary track record, spanning R&D, clinical practice, bioprocessing, regulation, healthcare economics, reimbursement and business.